The FDA has only approved six weight loss drugs, including: Bupropion-naltrexone (Contrave) Liraglutide (Saxenda) Orlistat (Xenical, Alli) Phentermine-topiramate (Qsymia) Semaglutide (Wegovy) Setmelanotide (Imcivree) Currently, the choice of weight loss drugs remains very limited and is divided into two main categories: pancreatic lipase inhibitors and appetite suppressants that act on the central nervous system
But long-term, microdose-specific data is still being collected, which is why these decisions need to be individualized
Yet, with their rising popularity, these wonder drugs are shrouded in myths and misconceptions
Side Effects and Safety Considerations The most common side effects in trials were gastrointestinal including nausea, vomiting, and diarrhoea and were dose-dependent
GLP-1 compounds are processed primarily through the kidneys and liver, so patients with moderate to severe kidney or liver disease should discuss GLP-1 therapy with their physician before starting
Operational Advantages for Modern Practices The introduction of an oral GLP-1 also has meaningful operational implications for clinics and med spas
